|
KMID : 1100120220290030191
|
|
대한골대사학회지
2022 Volume.29 No. 3 p.191 ~ p.196
|
|
|
Effects of the Revised Reimbursement Guideline for Anti-Osteoporosis Medication in South Korea
|
|
Ko Young-Seung
Jeong Yeon-Suk
Park Jung-Wee
Lee Young-Kyun
Koo Kyung-Hoi
|
|
|
Abstract
|
|
|
Background: The Korean National Health Insurance (NHI) reimbursement guideline was revised in May 2015 with the aim of preventing secondary osteoporotic fractures. Here we compared the: (1) rate of bone mineral density (BMD) measurements; (2) prescription rate of anti-osteoporosis medication within 3 months after hip fracture surgery (HFS); (3) incidence of a second hip fracture; and (4) first-year mortality rate after HFS.
Methods: This before-after study used the revised reimbursement system as a reference period. We retrospectively reviewed the medical records of 515 patients who underwent HFS at a tertiary referral hospital between January 2014 and December 2016. The period 1 group underwent HFS in 2014, while the period 2 group underwent HFS in 2016.
Results: Despite the fact that there was no significant intergroup difference in BMD measurement rate, the period 2 group had a higher prescription rate for anti-osteoporosis drugs within 3 months of HFS. However, the incidence of a second hip fracture did not differ between groups. The first-year mortality rate was higher in the period 1 versus period 2 group.
Conclusions: Revision of the NHI guideline in May 2015 was associated with an increased prescription rate of anti-osteoporosis medication in osteoporotic hip fracture patients.
|
|
|
KEYWORD
|
|
|
Hip fractures, Mortality, Osteoporosis
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
 
|